Susan Haigney

PharmTech Weekly Roundup—August 7, 2026

 featured articles about how policymakers are rewriting the rules for how drugs get made, including an approval for a messenger RNA (mRNA) vaccine and the White House’s blueprint pushing deregulation. Manufacturers are wrestling with whether their own systems, partnerships, and data can keep pace with the evolving regulatory system.

, the first mRNA flu vaccine, after initially refusing to review the application earlier in the year, saying more data were needed. Will this clearance test out the platform's manufacturing case against a backdrop of federal mRNA funding cuts?

In late July 2026, the White House Office of Science and Technology Policy released the report, 

, which holds up pharma's recent deregulation as a model for other sectors while pushing reshoring and new funding pathways beyond the standard NIH grant.

 for more on recent regulatory actions and upcoming agency meetings.

On August 4, Pathos AI agreed to pay $125 million upfront to a subsidiary of Alphamab Oncology for rights to an experimental treatment for triple-negative breast cancer. The 

 may see the AI-driven “Foundry” platform reshaping how oncology assets get selected, as cross-border deals increasingly hinge on manufacturing coordination across jurisdictions.

Dr. Hui-Yin (Harry) Li of Wilmington PharmaTech told 

 that sponsor-contract manufacturing organization relationship breakdowns rarely stem from weak quality agreements but from unclear communication and escalation pathways, making tiered governance the real differentiator.

 AI tools have arrived, but organizational readiness, employee sentiment, and data governance are now the real bottleneck.

Across this week's stories, it appears that policy and platforms are advancing quickly, but governance, data, and manufacturing coordination will be essential for success. For the full stories, visit 

Click the video to above to watch this week’s highlights.

Videos

This week’s content included Moderna's mRNA flu approval, CMO governance tips, OSTP’s deregulation push, a $2 billion oncology license, and July's regulatory wrap-up.

melanoma diagnosis. the doctor examines the patient's mole | Image Credit: ©Evgeniy Kalinovskiy -stock.adobe.com

The FDA announced on August 6, 2026 that it has approved Replimune’s Tudriqev (vusolimogene oderparepvec-wtpg) for the treatment of unresectable advanced cutaneous melanoma in adults who experience disease progression with a programmed death receptor-1 (PD-1)-blocking antibody-based regimen.

 Tudriqev, which is approved for use in combination with nivolumab, is a genetically modified oncolytic viral therapy. The treatment was approved through the agency’s accelerated approval pathway and was granted Breakthrough Therapy and Priority Review designations.

“This is a transformative moment for Replimune, marking years of pioneering research to bring TUDRIQEV to patients desperately in need of new treatment options for advanced melanoma,” said Sushil Patel, PhD, CEO of Replimune, in a press release.

 “We are deeply grateful to the melanoma community, including patients and investigators who participated in the clinical trial, for their tremendous support of this approval. We also would like to thank the FDA for recognizing the urgency to get this therapy to patients. Replimune is now focused on critical activities to deliver TUDRIQEV to as many patients as possible.”

According to the FDA, “Anti-PD-1 refractory melanoma is advanced skin cancer that no longer responds to a widely used class of immunotherapy drugs. Despite treatment, the cancer may continue to grow because of developed mechanisms to evade the immune system’s ability to detect and destroy it.”

The therapy is based on a modified herpes simplex virus type 1 (HSV-1) engineered to target and destroy cancer cells. The virus replicates itself inside a tumor and breaks the cancer cells apart, while also stimulating the body’s immune system to attack the cancer. It is injected directly into tumors once every 2 weeks for 8 consecutive doses. Dosage is determined by the size of the tumor. Used in combination with nivolumab, which is an anti-PD-1 immunotherapy, the FDA believes Tudriqev may create an anti-tumor immune response in patients. Nivolumab is given intravenously to patients beginning at the third week of treatment.

“For patients with advanced melanoma that has stopped responding to PD-1 blocking therapy, the prognosis is often devastating, and options have been far too limited. Clinicians managing these patients know this urgency firsthand,” said Karim Mikhail, B. Pharm., M.S., acting director of the FDA’s Center for Biologics Evaluation and Research, in a press release.

 “Today’s important milestone gives oncologists a meaningful new tool—and more patients a fighting chance.”

“Advanced melanoma patients have few options after anti-PD-1 therapy and face high morbidity and poor survival outcomes,” said Michael K. Wong, MD, PhD, primary investigator of the IGNYTE study and Former Physician in Chief and Professor of Oncology at Roswell Park Comprehensive Cancer Center in Buffalo, NY, in a press release.

 “With the approval of Tudriqev, we have a potent oncolytic immunotherapy that can be used in a broad population, including BRAF-naïve or pretreated, and adjuvant relapsed patients. Importantly, the therapy in combination with nivolumab drives immune activation with a favorable risk-benefit profile and can be injected into superficial and visceral lesions.”

The drug’s approval was based on data from an open-label, multiregional, single arm clinical trial that showed 1 in 4 patients responded to treatment. This positive response lasted a medium of nearly 14 months. The trial consisted of 140 adults with Stage IIIB, IIIC, or IV unresectable advanced melanoma whose disease had progressed for at least 8 consecutive weeks of being treated with an anti-PD-1-based therapy.

The agency also considered input from clinical experts and patient advocates in its approval decision. A meeting to discuss the application was held on July 30, 2026, and included patients, patient advocates, clinicians, and independent experts.

Adverse reactions reported with use of Tudriqev were mild and included fatigue, fever (pyrexia), infections, chills, musculoskeletal pain, nausea, diarrhea, injection site reaction, headache, cough, influenza-like illness, rash, vomiting, itching (pruritus), arthralgia, constipation, decreased appetite, dizziness, dyspnea, hemorrhage, edema, and abdominal pain. There is a risk of spreading a herpes infection to others or a herpes infection developing in patients.

“The approval of RP1 in combination with nivolumab is a meaningful step forward for patients with advanced melanoma who have failed to benefit from immunotherapy,” said Sam Guild, President of AIM at Melanoma, in a press release.

 “Every year, more than 8500 people die of melanoma in the US, and new treatment options are urgently needed.”

Some of the challenges associated with the manufacture of this type of product is the live-virus good manufacturing practice burden. Because this is a genetically engineered, replication-competent HSV-1, production may require dedicated biocontainment infrastructure, such as BSL-2 viral vector suites, segregated air handling, and strict facility controls to prevent cross-contamination with other biologics on site. The treatment also comes with cold-chain and site-of-care logistics due to the fact that it is injected intratumorally in a clinical setting, which requires cold-chain distribution and just-in-time delivery coordination with infusion/injection centers.

FDA approves new engineered viral immunotherapy for patients with treatment-resistant advanced melanoma. Press release. FDA. August 6, 2026. Accessed August 7, 2026. 

https://www.fda.gov/news-events/press-announcements/fda-approves-new-engineered-viral-immunotherapy-patients-treatment-resistant-advanced-melanoma

Replimune announces FDA accelerated approval of Tudriqev in combination with nivolumab for unresectable advanced cutaneous melanoma after progression on an anti-PD-1-based regimen. Press release. Relimune. August 6, 2026. Accessed August 7, 2026. https://ir.replimune.com/news-releases/news-release-details/replimune-announces-fda-accelerated-approval-tudriqevtm

Robilotti E, Zeitouni NC, Orloff M. Biosafety and biohazard considerations of HSV-1-based oncolytic viral immunotherapy. 

https://pmc.ncbi.nlm.nih.gov/articles/PMC10546393/

Beyer S, Lipinski K. Specialized know-how and capacity to support demand for oncolytic viruses. 

. March 19, 2020. https://www.pharmasalmanac.com/articles/specialized-know-how-and-capacity-to-support-demand-for-oncolytic-viruses

Articles

FDA granted accelerated approval to Replimune’s intratumoral oncolytic HSV-1 therapy Tudriqev (vusolimogene oderparepvec-wtpg) plus nivolumab for adults with unresectable advanced cutaneous melanoma progressing after PD-1 blockade. Breakthrough Therapy and Priority Review supported the decision. In the single-arm, open-label IGNYTE study (n=140; stage IIIB–IV), objective response was ~25% with median response duration ~14 months. Adverse events were largely mild flu-like and local effects, with herpes transmission/infection risk. Manufacturing demands include live-virus GMP biocontainment and cold-chain, just-in-time clinic logistics.

The genetically modified oncolytic viral therapy, used in combination with nivolumab, was approved by the agency after data showed 1 in 4 patients responded to treatment.

The FDA Gives Accelerated Approval to Melanoma Treatment

The pharmaceutical timeline from discovery to market is a long, complex process. Sponsor companies often use contract organizations, such as contract manufacturing organizations (CMOs), to perform a bulk of the manufacturing processes. Because the sponsor companies, in the eyes of regulators, have the ultimate responsibility to ensure the safety, quality, and efficacy of drug products, maintaining a healthy relationship with CMOs that includes oversight is imperative.

But how is this relationship created and maintained in a way that benefits both sponsor and contractor? 

 spoke with Dr. Hui-Yin (Harry) Li, president and CEO of Wilmington PharmaTech, to understand how these relationships are built and nourished.

PharmTech:How do pharmaceutical companies establish clear quality agreements with CMOs, and what governance structures have you seen effectively align expectations on both sides of the relationship from day one?

A strong sponsor–CMO relationship starts with a well-defined quality agreement that clearly assigned responsibilities for good manufacturing practice (GMP) compliance, quality systems, change control, deviations, investigations, corrective actions and preventive actions (CAPA), regulatory communications, audits, and product release. The agreement should be developed collaboratively and aligned with the commercial contract, technology transfer plan, and regulatory strategy.

Quality agreements typically receive substantial attention during contract negotiations, while governance structures often receive less. In my experience, more challenges arise from unclear communication pathways, decision-making authority, or escalation processes than from the agreement wording.

A quality agreement sets the foundation. Effective governance is what keeps the relationship aligned throughout the program. Strong partnerships establish a tiered structure from the outset with executive sponsors, operational project teams, and quality representatives. Regular joint meetings, defined escalation pathways, and clear decision-making responsibilities keep both parties aligned. Early agreement on communication expectations, risk tolerance, timelines, and success criteria prevents misunderstandings later on.

What communication cadences and data-sharing practices are most effective in building transparency with a contract manufacturer, particularly when deviations or supply disruptions arise?

Transparency is built through consistent communication long before a problem occurs. For active development or manufacturing programs, weekly operational meetings and monthly management reviews are often effective. These meetings should cover project status, manufacturing schedules, quality metrics, change controls, supply chain risks, and upcoming milestones.

When deviations, investigations, or supply disruptions occur, timely communication matters even more. In my experience, sponsors rarely get upset because a deviation occurred; they get upset when they learn about it late. Most sponsors understand that manufacturing is complex and issues can happen. What they expect is prompt notification, transparency, and a credible resolution plan. Sharing data, root-cause analyses, risk assessments, and CAPA plans maintain trust and facilitates collaborative problem solving. Sponsors are far more understanding when informed promptly and involved appropriately, rather than learning about issues after significant delays.

How can sponsors companies maintain meaningful technical oversight without creating an adversarial dynamic or micromanaging the CMO's operations? What governance mechanisms work well?

The most productive sponsor–CMO relationships focus oversight on outcomes, compliance, and risk management rather than day-to-day operations. Sponsors should recognize that CMOs have established quality systems, manufacturing expertise, and operational processes that support multiple clients and regulatory requirements.

A common challenge arises when sponsors manage individual manufacturing activities rather than focusing on process performance, quality outcomes, and key risks. The CMO was selected for its expertise, which should be leveraged while maintaining appropriate visibility into quality, compliance, and program risks. The most effective relationships allow the CMO to execute within its established quality systems and operating procedures while providing sponsors with the oversight they need.

A balanced approach includes regular technical review meetings, periodic quality reviews, milestone-based decision points, and clearly defined escalation procedures. Joint steering committees or technical review boards work well for complex programs because they provide a structured forum for discussing process performance, technology transfer progress, quality trends, and strategic decisions. Clear expectations for what information is shared, when, and who has decision-making authority prevent micromanagement while ensuring appropriate oversight. When both parties approach discussions as partners, oversight becomes collaborative rather than adversarial.

In your experience, what contractual or relational incentives most effectively motivate CMOs to treat a sponsor's product with the same priority and care they would a proprietary one, and how do you sustain that motivation over a multi-year engagement?

Contracts establish expectations, but long-term success is usually driven by relationships and mutual business value. Multi-year programs, predictable forecasting, transparent planning, and credible opportunities for future work give CMOs strong incentives to invest resources and attention in a sponsor's products.

From a CMO’s perspective, one of the strongest motivators is visibility into a sponsor's long-term plans. When sponsors share realistic forecasts, future development opportunities, and commercial expectations, CMOs are more willing to invest resources, dedicate technical expertise, and proactively support the program's success.

The strongest long-term relationships are those where the sponsor views the CMO as a strategic partner rather than simply a vendor. Sponsors that share long-term product plans, involve the CMO in technical discussions, and recognize its contributions often receive greater engagement and commitment. Sustaining motivation over multiple years requires open communication, fair resolution of challenges, realistic expectations, and a shared focus on patient outcomes and commercial success. When both organizations treat the relationship as a mutual benefit partnership, priorities naturally align. When every project is treated as a standalone transaction, it becomes much harder for either side to make the long-term investments that drive operational excellence and continuous improvement.

How can pharma sponsors foster a genuine culture of continuous improvement with their CMO partners, moving beyond compliance-as-a-floor toward a shared commitment to quality that drives and innovation in manufacturing processes?

Continuous improvement succeeds when quality is a shared responsibility not just a contractual obligation. Even for well-established late-stage and commercial products, there’s always room to improve execution, reliability, and operational efficiency. Sponsors and CMOs should routinely review process performance, manufacturing trends, deviations, investigations, and operational metrics to improve robustness and reduce risk while maintaining regulatory compliance.

Some of the most valuable improvements come from joint reviews after manufacturing campaigns are completed. Beyond deviations, sponsors and CMOs can review metrics such as yield, cycle time, equipment utilization, right-first-time performance, and recurring operational challenges. These discussions often identify opportunities to improve manufacturing consistency, strengthen supply reliability, and reduce operational risk without changing the underlying manufacturing process.

The strong sponsor-CMO relationships formalize these discussions through periodic business reviews, technical reviews, and lessons-learned sessions. When both organizations share common goals around quality, reliability, supply continuity, and operational excellence, continuous improvement becomes part of the partnership rather than simply a compliance exercise. The result is a more reliable manufacturing operation that consistently delivers high-quality product to patients.

FDA. Contract Manufacturing Arrangements for Drugs: Quality Agreements, Guidance for Industry. CDER, CBER. November 2026. Accessed August 4, 2026. 

Munk M, Boldt V, Chang A. Navigating the CDMO-sponsor partnership. 

 August 13, 2024. Accessed August 4, 2026. 

https://pda.org/pda-letter-portal/home/full-article/navigating-the-cdmo-sponsor-partnership

Dr. Hui-Yin (Harry) Li, president and CEO of Wilmington PharmaTech

Dr. Hui-Yin (Harry) Li has more than 30 years of combined experience in all aspects of new drug research and development, including API current GMP manufacturing (CGMP), solid state chemistry, and project management. He is the author of numerous patents and publications, including key process and polymorph patents related to several important pharmaceutical compounds. In 2003, Li founded Wilmington PharmaTech with 3 CGMP production facilities, an R&D center in Newark, Delaware, and a research center in Suzhou, China, and he continues to serve as President and CEO. Li received a B.S. in chemistry from Nanjing University of Science and Technology, an M.S. in natural product chemistry from Shanghai Institute of Materia Medica, Chinese Academy of Sciences, and a Ph.D. in organic chemistry from Tokyo Institute of Technology. From 1990 to 1991, he was a post-doctoral fellow at the Medical Products Department of DuPont Company. After working as a medicinal chemist with DuPont Merck Pharmaceuticals from 1991 to 1995, he worked as a process chemist at the Process R&D department of DuPont Pharmaceuticals Company (1995-2001) and Bristol-Myers Squibb (2001-2002). Li is also an adjunct professor at the University of Delaware and Shanghai Institute of Materia Medica, Chinese Academy of Sciences in China.

Sponsor companies retain regulatory accountability for product safety, quality, and efficacy, making structured, transparent CMO partnerships essential. Effective engagement begins with collaboratively built quality agreements covering GMP responsibilities, change control, deviations, CAPA, audits, and release, aligned to commercial and tech-transfer plans. Governance—clear decision rights, escalation paths, and tiered forums from executive to operational teams—prevents most friction. Proactive cadence, rapid deviation notification, and sharing of root-cause and CAPA data sustain trust. Long-term alignment and continuous improvement emerge from forecasting transparency, joint performance reviews, and post-campaign lessons learned.

PharmTech spoke with Dr. Hui-Yin (Harry) Li, president and CEO of Wilmington PharmaTech, about steps that should be taken to build a productive relationship between sponsor and contract organizations.

How to Maintain a Productive Sponsor-CMO Relationship

Regulatory Roundup for July 2026

This month in pharmaceutical regulations, in the United States, the FDA proposed modernizing the regulatory infrastructure that governs how drugs are made, and expanded patient access to treatments across oncology, cardiometabolic disease, neurology, and rare genetic disorders.

 that would let distributed “hub-and-spoke” manufacturing networks register as a single establishment, while also closing a registration gap for foreign API makers to improve supply chain visibility.

According to Henrik Johanning, senior vice president, Quality & Strategy at Epista, “Registering a distributed network as a single establishment is the right move operationally, but it consolidates quality accountability rather than reducing it. 'One establishment' only holds up if the central quality hub genuinely controls every manufacturing unit,” Johanning told 

. “The same quality system, data integrity, and lifecycle discipline across equivalent sites. The administrative simplification is indeed welcome; what it concentrates in the hub is exactly what manufacturers should be planning for.”

Manish Garg, a track and trace specialist, told 

that, in his own personal opinion, “The proposed hub-and-spoke registration pathway is narrower than it may first appear. It applies to a specifically defined distributed-manufacturing model which is equivalent manufacturing units operating under a single quality unit and unified pharmaceutical quality system and not to conventional multi-site or CMO-based networks. That distinction matters because, if the rule is finalized, the practical challenge for qualifying manufacturers will not simply be administrative. It will be maintaining two levels of identity and visibility across the same operating network: a consolidated establishment identity and precise unit-level operational records.”

“FDA may allow a qualifying distributed manufacturing establishment to register as one establishment, but its individual units would not become operationally invisible. The proposal would still require an identifier and location information for each distributed manufacturing unit, including advance notification of relocation,” Garg continued. “Manufacturers would therefore need to preserve reliable relationships among FDA registration data, unit locations, quality systems, regulatory submissions, and manufacturing records and, where serialized finished products are involved, the location master data used in traceability systems. A single FDA establishment identity should not be interpreted as permission to collapse the physical-location detail upon which batch genealogy, investigations, inspections, and recalls depend.”

“The foreign-establishment provision may have the more immediate supply-chain impact. By aligning the regulations with the PREVENT Pandemics Act, FDA is clarifying that certain foreign establishments, which includes API manufacturers, would be expressly required to register and provide drug-listing information even when their products undergo further processing at another foreign establishment before reaching the United States,” Garg told 

. “Prior regulations did not directly address this fact pattern; the proposal would close that regulatory visibility gap.This is not ingredient-level serialization or DSCSA-style event-level traceability: it does not create serialized API identifiers or require electronic event exchange for upstream materials. It is, however, a meaningful step toward stronger upstream visibility. The broader signal is that regulatory identity, manufacturing-location data, quality records, and supply-chain data can no longer be governed in entirely separate organizational silos.”

And Jason Bock, founder and CEO of CTMC, provides his perspective on the FDA’s proposed rule to streamline registration for single distributed manufacturing establishments, and what the change may mean for personalized medicines, in 

FDA Updates Guidance and Approves Medicines

In other US regulation updates, the FDA revised draft product-specific guidance documents for 

—including semaglutide and tirzepatide—tightening expectations for immunogenicity testing, impurity thresholds, and structural characterization ahead of a September comment deadline.

The agency also published guidance regarding the development of psychedelic drugs.

See below for more guidance documents published in July.

The agency approved several medications in July for the treatment of lung and breast cancer, Alzheimer’s, and other conditions. FDA also approved Casgevy, the CRISPR-based gene therapy, for children as young as two with sickle cell disease or transfusion-dependent beta thalassemia, marking the youngest approved age group for gene-editing therapy.

Together, these actions show FDA balancing streamlined manufacturing oversight with an accelerating pace of therapeutic innovation.

What’s New in European Pharma Regulations?

In Europe, activity by the European Medicines Agency (EMA) centered on regulatory modernization paired with expanding access to innovative therapies, such as new phased-review pathways, first-in-class oral and implantable medicines, and continued vigilance on drug safety and health equity.

EMA and the European Union's Innovation Council agency, EISMEA, deepened their partnership

 to help SMEs and biopharma innovators engage with regulatory requirements earlier in development, reducing risk and speeding novel therapies toward patients.

In her final annual address to the European Parliament's health committee, EMA's Executive Director highlighted 104 positive medicine recommendations in 2025 and outlined how the EU's incoming pharmaceutical framework will shorten evaluation timelines and strengthen critical medicines supply chains.

EMA's human medicines committee recommended 12 new medicines in July, including 3 cholesterol therapies and a rare-disease treatment under exceptional circumstances, while rejecting 3 applications and updating COVID-19 vaccines for the new XFG variant.

The United Kingdom’s Medicines and Healthcare products Regulatory Agency (MHRA) saw record regulatory performance and growing international standing, while reinforcing patient safety vigilance and transparency around UK medicines.

According to MHRA's 2025-26 Annual Report 921 medicines were approved in the past year, and the agency created new frameworks for AI and rare disease regulation—cementing the agency's growing global regulatory influence.

MHRA strengthened safety warnings across all botulinum toxin type A products following rare cases of iatrogenic botulism, urging patients and prescribers to recognize symptoms like difficulty swallowing, slurred speech, or breathing problems that can appear up to four weeks after treatment.

In compendia news, EDQM's classification committee published new evidence-based reviews assessing non-prescription status for paracetamol-ibuprofen combinations and naloxone, guiding how EU member states classify these products for supply.

 general chapter 5.1.6 that modernizes alternative microbiological methods, clarifying supplier and user responsibilities and introducing risk-based validation strategies ahead of an April 2027 implementation date.

 launched their first trilateral prospective harmonization project, co-developing unified quality standards for osimertinib mesilate and its tablets to reduce duplicate testing across regions.

The European Pharmacopoeia Commission adopted 93 new and revised texts at its 185th session, including new monographs for olaparib and adalimumab, an anti-adulteration test for sorbitol and maltitol, and plans for a working party on 3D-printed medicines.

EDQM opened public consultation on two new European Drug Shortages Formulary monographs, for quetiapine capsules and a sulfamethoxazole/trimethoprim suspension, giving manufacturers standardized formulas to help mitigate supply shortages.

EDQM released Pharmeuropa 38.3 with 40 draft monographs and general chapters open for public comment through September 30, covering products from ezetimibe to an RSV vaccine, urging manufacturers to weigh in before drafts become binding standards.

EDQM and USP's joint Stakeholder Forum reaffirmed their long-running prospective harmonization partnership, with forum insights now available in a free on-demand course to help industry track global pharmacopoeial alignment.

These updates underscore EDQM's focus on accelerating international standards harmonization while keeping the door open for industry input before new requirements take effect.

For more on these and other stories, visit PharmTech.com

FDA Proposes Rule to Modernize Drug Manufacturing Registration. Press release. FDA. July 10, 2026. Accessed July 31, 2026 

https://www.fda.gov/news-events/press-announcements/fda-proposes-rule-modernize-drug-manufacturing-registration

FDA Publishes Revised Draft Product-Specific Guidances for Certain Generic Peptide Products. FDA.gov. Accessed July 31, 2026.  

https://www.fda.gov/drugs/drug-alerts-and-statements/fda-publishes-revised-draft-product-specific-guidances-certain-generic-peptide-products

Psychedelic Drugs: Considerations for Clinical Investigations. Guidance for Industry

. FDA. July 2026. Accessed July 31, 2026. 

https://www.fda.gov/regulatory-information/search-fda-guidance-documents/psychedelic-drugs-considerations-clinical-investigations

FDA Approves First Gene Therapy for Young Children with Sickle Cell Disease. Press release. FDA. July 1, 2026. Accessed July 31, 2026. 

https://www.fda.gov/news-events/press-announcements/fda-approves-first-gene-therapy-young-children-sickle-cell-disease

EMA and EISMEA boost cooperation to accelerate health innovations. Press release. EMA. July 15, 2026. Accessed July 31, 2026. 

https://www.ema.europa.eu/en/news/ema-eismea-boost-cooperation-accelerate-health-innovations

Executive Director Emer Cooke's speech at the European Parliament's Committee on Public Health. Press release. July 14, 2026. Accessed July 31, 2026. 

https://www.ema.europa.eu/en/news/executive-director-emer-cookes-speech-european-parliaments-committee-public-health

Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 20-23 July 2026. Press release. EMA. July 24, 2026. Accessed July 31, 2026. 

https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-20-23-july-2026

MHRA delivers record performance as 2025-26 Annual Report and Accounts confirms growing global influence

Press release. MHRA. July 16, 2026. Accessed July 31, 2026. 

https://www.gov.uk/government/news/mhra-delivers-record-performance-as-2025-26-annual-report-and-accounts-confirms-growing-global-influence

Updated warnings for botulinum toxin products following rare cases of botulism. Press release. MHRA. July 15, 2026. Accessed July 31, 2026. 

https://www.gov.uk/government/news/updated-warnings-for-botulinum-toxin-products-following-rare-cases-of-botulism

CD-P-PH/PHO publishes two new evidence-based classification reviews. Press release. EDQM. July 20, 2026. Accessed July 31, 2026. 

https://www.edqm.eu/en/-/cd-p-ph/pho-publishes-two-new-evidence-based-classification-reviews

Publication of revised Ph. Eur. general chapter 5.1.6 on alternative microbiological methods. Press release. EDQM. July 15, 2026. Accessed July 31, 2026. 

https://www.edqm.eu/en/-/publication-of-revised-ph.-eur.-general-chapter-5.1.6-on-alternative-microbiological-methods

Ph. Eur., JP and USP announce the launch of a trilateral prospective harmonisation project on pharmacopoeial standards for osimertinib mesilate and osimertinib tablets. Press release. EDQM. July 13, 2026. Accessed July 31, 2026. 

https://www.edqm.eu/en/-/ph.-eur.-jp-and-usp-announce-the-launch-of-a-trilateral-prospective-harmonisation-project-on-pharmacopoeial-standards-for-osimertinib-mesilate-and-osimertinib-tablets

Outcome of the 185th session of the European Pharmacopoeia Commission. Press release. EDQM. July 9, 2026. Accessed July 31, 2026. 

https://www.edqm.eu/en/-/outcome-of-the-185th-session-of-the-european-pharmacopoeia-commission

Second issue of Pharmeuropa EDSForm published: two new draft European Drug Shortages Formulary monographs are now available for public consultation. Press release. EDQM. July 6, 2026. Accessed July 31, 2026. 

https://www.edqm.eu/en/-/second-issue-of-pharmeuropa-edsform-published-two-new-draft-european-drug-shortages-formulary-monographs-are-now-available-for-public-consultation

Pharmeuropa 38.3 just released. Press release. July 1, 2026. Accessed July 31, 2026. 

https://www.edqm.eu/en/-/pharmeuropa-38.3-just-released

USP-EDQM Stakeholder Forum reinforces commitment to pharmacopoeial collaboration and global alignment. Press release. EDQM. July 27, 2026. Accessed July 31, 2026. 

https://www.edqm.eu/en/-/usp-edqm-stakeholder-forum-reinforces-commitment-to-pharmacopoeial-collaboration-and-global-alignment

FDA Approves New Treatment to Reduce Proteinuria in Adults with Primary Immunoglobulin A Nephropathy

https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-new-treatment-reduce-proteinuria-adults-primary-immunoglobulin-nephropathy

FDA Approves First Oral Therapy that Inhibits Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) to Lower Bad Cholesterol in Adults with High Cholesterol


https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-first-oral-therapy-inhibits-proprotein-convertase-subtilisinkexin-type-9-pcsk9-lower

FDA approves gedatolisib with fulvestrant, with or without palbociclib, for HR-positive, HER2-negative locally advanced or metastatic breast cancer

https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-gedatolisib-fulvestrant-or-without-palbociclib-hr-positive-her2-negative-locally

FDA grants traditional approval to selpercatinib for locally advanced or metastatic RET fusion-positive solid tumors

https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-traditional-approval-selpercatinib-locally-advanced-or-metastatic-ret-fusion-positive

FDA Approves First At-home Starting Dose for Alzheimer’s Disease Treatment

https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-first-home-starting-dose-alzheimers-disease-treatment

FDA approves isatuximab-irfc for subcutaneous injection for multiple myeloma indications

https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-isatuximab-irfc-subcutaneous-injection-multiple-myeloma-indications

FDA approves pembrolizumab or pembrolizumab and berahyaluronidase alfa-pmph each with enfortumab vedotin-ejfv for muscle invasive bladder cancer

https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-pembrolizumab-or-pembrolizumab-and-berahyaluronidase-alfa-pmph-each-enfortumab-vedotin

FDA Approves First Gene Therapy for Young Children with Sickle Cell Disease

FDA approves zidesamtinib for ROS1-positive non-small cell lung cancer

https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-zidesamtinib-ros1-positive-non-small-cell-lung-cancer

FDA Approves First Nonprescription Fixed-Dose Combination of Acetaminophen and Naproxen Sodium for 12-Hour Pain Relief

https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-first-nonprescription-fixed-dose-combination-acetaminophen-and-naproxen-sodium-12-hour

FDA Guidance Documents Issued in July 2026

Psychedelic Drugs: Considerations for Clinical Investigations

Formal Meetings Between the Food and Drug Administration and Sponsors or Requestors of Over-the-Counter Monograph Drugs

https://www.fda.gov/regulatory-information/search-fda-guidance-documents/formal-meetings-between-food-and-drug-administration-and-sponsors-or-requestors-over-counter

Topical Dermatologic Corticosteroids: In Vivo Bioequivalence

https://www.fda.gov/regulatory-information/search-fda-guidance-documents/topical-dermatologic-corticosteroids-in-vivo-bioequivalence-0

Submitting Next-Generation Sequencing Data to the Division of Antiviral Products

https://www.fda.gov/regulatory-information/search-fda-guidance-documents/submitting-next-generation-sequencing-data-division-antiviral-products

FDA, Warning Letter to International Medication Systems Limited, July 2, 2026. Accessed July 31, 2026


https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/international-medication-systems-limited-727560-07022026

FDA 
Drug Repurposing: Considerations for Selection Criteria and Prioritization

https://www.fda.gov/drugs/news-events-human-drugs/drug-repurposing-considerations-selection-criteria-and-prioritization-08052026

FDA Public Meeting: FDA-Led Patient-Focused Drug Development Meeting for Nonhealing Chronic Wounds

https://www.fda.gov/drugs/news-events-human-drugs/fda-public-meeting-fda-led-patient-focused-drug-development-meeting-nonhealing-chronic-wounds

Virtual Workshop on Digital Health Technologies and Statistical Considerations for Digitally-Derived Endpoints in Clinical Trials

https://www.fda.gov/drugs/news-events-human-drugs/fda-virtual-workshop-digital-health-technologies-and-statistical-considerations-digitally-derived

Advancing Generic Drug Development: Leveraging Model-Integrated Evidence (MIE) in the Development & Approval of Generic Drugs


https://www.fda.gov/drugs/news-events-human-drugs/advancing-generic-drug-development-leveraging-model-integrated-evidence-mie-development-approval

Meeting of the Medicine Shortages Single Point of Contact (SPOC) Working Party

https://www.ema.europa.eu/en/events/meeting-medicine-shortages-single-point-contact-spoc-working-party-44

Modernizing infrastructures, record drug approvals, and harmonization were all positive regulatory advancements in July 2026.

Regulatory Roundup—July 2026

PharmTech Weekly Roundup—July 31, 2026

, the theme of promise to practice was obvious. AI is being utilized in drug discovery, but plant-floor execution still lags behind. Regulators are modernizing rules for advanced therapies and peptides. And manufacturers are rethinking where and how they build capacity, transfer technology, and monitor quality in real time.

 to consolidate R&D at Cambridge Biomedical Campus while closing Stevenage and expanding scale-up manufacturing at Ware, reflecting a trend of placing research near academic and clinical hubs.

FDA revised draft guidance documents for 17 generic peptide products

 tightening expectations for impurity testing, immunogenicity, and structural analysis ahead of a September comment deadline.

 industry update continues. Halfway through the year, 

experts agree that next-generation modalities like ADCs and GLP-1s are advancing quickly

, but regulatory compliance and organizational readiness remain the industry's toughest execution hurdles.

Cheryl Barton, a contributing writer for PharmTech Europe, highlights how 

European biotechs are using AI-driven target discovery

 to push respiratory treatment beyond broad immunosuppression toward precision therapies for asthma, COPD, and pulmonary fibrosis.

 with his take on the FDA's proposed single-registration rule for distributed “hub-and-spoke” networks

. He says the rule could give personalized cell and gene therapy makers the regulatory clarity to build patient-proximate supply chains. 

Bock adds that earning FDA's trust under this streamlined model

 will require manufacturers to adopt fully digital, harmonized quality systems so deviations and corrective actions can be shared instantly across every site.

Content on PharmTech.com this week showed that while AI is being utilized in drug discovery, manufacturing execution still lags behind. However, manufacturers are rethinking where and how they build capacity, transfer technology, and monitor quality in real time.